Intelligence · Clinical Development
Pipeline search results
Programs matching “powder” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 47 pipeline programs matching "powder" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
REZZAYO 200 mg powder for concentrate for solution for infusion
Mundipharma Pty Limited
Chronic pulmonary aspergillosis (CPA)
1 trial -
Reblozyl 75 mg powder for solution for injection
GlaxoSmithKline
Myelofibrosis
1 trial -
Topical Powder
Dermata Therapeutics
Acne Rosacea
1 trial -
Trodelvy 200 mg powder for concentrate for solution for infusion
Gilead Sciences Pty Limited
Metastatic Solid Tumors
1 trial -
Vaborem 1 g/1 g powder for concentrate for solution for infusion
A.Menarini Australia Pty Limited
Suspected or confirmed Gram negative infections
1 trial -
Veklury 100 mg powder for concentrate for solution for infusion
MEDA Pharma GmbH & Co. KG
COVID-10 infection
1 trial -
albuterol inhalation powder
Amphastar France Pharmaceuticals
Asthma
1 trial -
sotatercept, PL1 - Powder for injection
Lacuna Pharma Pty Ltd
Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)
1 trial -
Albuterol dry powder inhaler
Teva Pharma GmbH
Asthma
1 trial -
BIO 300 Oral Powder
United Therapeutics Europe Ltd
Acute Radiation Syndrome
1 trial -
GC4702 dry powder
Galera Therapeutics
Healthy Volunteer
1 trial -
ONC206 Powder
AXIM BIOTECHNOLOGIES, INC.
Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors
1 trial -
Treprostinil Inhalation Powder
United Therapeutics Europe Ltd
Pulmonary Arterial Hypertension
1 trial -
Enbrel powder and solvent for Juvenile Idiopathic Arthritis
Fondazione Telethon ETS
Juvenile Idiopathic Arthritis
1 trial -
Myozyme 50 mg powder for concentrate for solution for infusion
Disc Medicine
Pompe disease / glycogenosis type II / acid maltase deficiency
1 trial -
Myozyme powder for concentrate for solution f... for Pompe disease
Disc Medicine
Pompe disease
1 trial -
Nexviadyme 100 mg powder for concentrate for solution for infusion
Disc Medicine
Glycogen storage disease type II or acid maltase deficiency, Pompe disease
1 trial -
Remsima 100 mg powder for concentrate for solution for infusion
Disc Medicine
Crohn's Disease
1 trial -
Xiang Sha Liu Jun Zi Decoction dry powder
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma
1 trial -
BEAM Dream Powder
Beam Therapeutics
Sleep
1 trial -
Beam Organics Dream Powder
Beam Therapeutics
Sleep
1 trial -
Beverage powder fortified with micronutrients and Bacopa monnieri extract
COGNITION THERAPEUTICS INC
Cognition
1 trial -
Gluten Powder
Regeneron UK Limited
Celiac Disease
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.